New drug RBD1119 put to the test in healthy volunteers for first time
NCT ID NCT07042594
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This early-stage study tests the safety of a new drug, RBD1119, in 32 healthy adults aged 18 to 65. Participants receive a single injection of either the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. The goal is to gather initial safety data, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research
Adelaide, Australia
Conditions
Explore the condition pages connected to this study.